Company Name: Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The company is engaged in the development of treatments for gastrointestinal, oncology-based inflammatory and ophthalmic disorders. The company’s marketed product, AMITIZA® (lubiprostone), is a treatment for chronic constipation, irritable bowel syndrome with constipation (IBS-C) in women, chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in patients with chronic non-cancer pain.
Ticker Symbol: SCMP (NASDAQ)
Company Website: www.sucampo.com
Headquarters: Bethesda, MD